DUBLIN, September 7, 2017 /PRNewswire/ --
The "Global Parkinson's Disease Drugs Market Outlook 2022" report has been added to Research and Markets' offering.
The global Parkinson's disease drugs market is anticipated to witness a moderate growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global Parkinson's disease drugs market. The report provides insight about the major drivers, such as increasing awareness about Parkinson's disease and its treatment options, research grants and funds, for the global Parkinson's disease drugs market.
Parkinson's disease belongs to the group of conditions called motor system disorders. This disease is a result of loss of dopamine producing neurons in the brain. The four primary symptoms of Parkinson's disease are tremors, rigidity, slowness of movement and postural instability. Although, there is no cure for Parkinson's disease, several medications are used to suppress the symptoms of the disease.
Furthermore, few challenges, such as patent expiry and high cost of treatment, which are hindering the growth of the global Parkinson's disease drugs market have also been mentioned in the report. In addition, the report also highlights various opportunities available for growth of the global Parkinson's disease drugs market.
The global Parkinson's disease drugs market has been segmented on the basis of type of therapy into levodopa therapy, dopamine therapy, MAO-B inhibitor therapy, COMT inhibitor therapy, and other types of therapies. Among all the types, levodopa therapy is the first and most potent treatment for the Parkinson's disease. The benefits of the medication are witnessed soon after administration.
Apart from these types of therapies, various pharmaceutical and biotech companies are also developing stem cell therapy for the treatment of Parkinson's disease. Stem cell therapy is an evolving field which makes use of stem cells to treat or prevent a disease or condition, such as Parkinson's disease. Even a minimal success from this procedure can mean significant improvement in quality of life for patients.
Numerous companies, such as SanBio Inc and International Stem Cell Corp, are carrying out clinical trials for stem cell therapies for the treatment of Parkinson's disease. Hence, stem cell therapy presents great opportunities for the growth of global Parkinson's disease drugs market in the coming years.
Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America accounted for the largest share in the global Parkinson's disease drugs market. Moreover, the report also highlights various mergers and acquisitions taking place in the global Parkinson's disease drugs industry. The drugs pipeline of Parkinson's disease has also been mentioned in the report.
Key Topics Covered:
1. Analyst View
2. Research Methodology
3. Parkinson's Disease: An Overview
4. Market Dynamics
4.1 Drivers
4.1.1 Increasing Funding Support & Research Grants
4.1.2 Increasing Awareness
4.1.3 Rising Healthcare Expenditure
4.1.4 Increasing Life Expectancy
4.2 Challenges
4.2.1 Patent Expiry of Blockbuster Drugs
4.2.2 High Cost of Treatment
4.2.3 Side Effects of Parkinson's Disease Drugs
4.3 Opportunities
4.3.1 Collaborations with Academic Institutions for Developing Innovative Solutions
4.3.2 Reduction in Off Time to Improve Patient and Economic Outcomes
4.3.3 Growing Geriatric Population
5. Global Parkinson's Disease Drugs Market Outlook 2022
6. Major Products in Parkinson's Disease Market
6.1 Duodopa/Duopa
6.2 Azilect
6.3 Mirapex/Mirapex ER
6.4 Requip
6.5 Neupro
6.6 Rytary/Numient
6.7 Xadago
6.8 Nuplazid
7. Market Segmentation by Type of Therapy
7.1 Levodopa Therapy
7.2 Dopamine Agonist Therapy
7.3 MAO-B Inhibitor Therapy
7.4 COMT Inhibitor Therapy
7.5 Other Therapy
8. Market Segmentation by Geography
8.1 North America
8.2 Europe
8.3 Asia-Pacific
9. Trends & Developments
9.1 Stem Cell Therapies - Revolutionizing Parkinson Treatment
9.2 Incessant Launch of Novel Products
10. Mergers & Acquisitions
11. Drugs Pipeline of Parkinson's Disease
12. Company Profiles
12.1 Abbvie Inc.
12.2 Newron Pharmaceuticals SpA
12.3 Acadia Pharmaceuticals Inc.
12.4 Boehringer Ingelheim International GmbH
12.5 Teva Pharmaceutical Industries Limited
12.6 GlaxoSmithKline plc
12.7 UCB S.A.
12.8 Novartis AG
12.9 Impax Laboratories, Inc.
12.10 Valeant Pharmaceuticals International, Inc.
12.11 Merck & Co., Inc.
12.12 Mylan N.V.
12.13 F. Hoffmann-La Roche Ltd.
12.14 US WorldMeds, LLC
For more information about this report visit https://www.researchandmarkets.com/research/l799tq/global
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
